Pick Disease of the Brain

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

4 weeks ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

2 months ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Coya Therapeutics Faces Setback as COYA 302 Delivers Mixed Results in Mid-Stage Study for Frontotemporal Dementia

1 year ago talkbio0Tagged Alzheimer 's disease, Biotechnology, Clinical Trials, COYA, Neurodegenerative Disorders, Pick Disease of the Brain

Coya Therapeutics, COYA 302, Frontotemporal Dementia, Alzheimer’s Disease, Neurodegenerative Diseases, Clinical Trials, Biotechnology

Astellas Expands Gene Therapy Portfolio with $2.2 Billion Deal for AviadoBio’s Frontotemporal Dementia Treatment

1 year ago talkbio0Tagged Astellas Pharma Inc., AVB-101, AviadoBio Ltd., Frontotemporal dementia, gene therapy, Mutation, Neurodegenerative Disorders, Pick Disease of the Brain, Progranulins

Astellas Pharma Inc., AviadoBio Ltd., Gene Therapy, Frontotemporal Dementia, FTD-GRN, AVB-101, Progranulin Mutations, Neurodegenerative Diseases